ABCG2 and glioma: Although the inhibition of ABC transporters itself has not proven efficiency for the clinical delivery of drugs, they have been a key resource to deepen our knowledge of the function of ABC transporters, and the multidrug resistance in cancer, glioma, and other CNS pathologies, as well as their implications in the blood–brain interfaces.